Table 1.
The effects of altering FoxD5 levels on the cell-autonomous expression of neural ectodermal (NE) transcription factors
| NE gene | FoxD5 LOF | FoxD5 GOF | ||
|---|---|---|---|---|
| gastrula | neural plate | gastrula | neural plate | |
| gem | −, st12 | − | + | + |
| sox2 | − | − | −, w | nc |
| sox3 | −, st12 | − | −, w | nc |
| sox11 | − | − | −, w | + |
| soxD | − | − | nc | − |
| zic1 | − | + | − | − |
| zic2 | −, st12 | − | + | + |
| zic3 | − | + | − | − |
| Xiro1 | − | − | − | − |
| Xiro2 | − | − | − | − |
| Xiro3 | − | − | − | − |
Legend: LOF, loss-of-function by injecting foxD5-MOs; GOF, gain-of-function by injecting foxD5 mRNA; −, reduced gene expression; +, increased gene expression; nc, no change in gene expression; w, weak effect; st12, stage at which the foxD5-MOs-mediated reduction was first observed for gem, sox3 and zic2. Gastrula includes stages 10–12.5; neural plate includes stages 13–15.